drug · small molecule
admilparant
Phase 3updated 5mo agoby Bristol-Myers Squibb Co🔗 ChEMBL
Phase 3community read0 votes
Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 4 investigational indications.
indications
indications
Pulmonary Fibrosis
all catalysts(0)
nothing on the calendar yet
Trials studying admilparant
News(8)
- BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffsBMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for…biospace · 1d ago
- BMS reports liver injury events in lung disease program, with key readout nearBristol Myers Squibb will soon release Phase 3 data for admilparant that could make or break Contineum Therapeutics’ rival product. But reports of a death due to liver injury in the pharma’s progra…biospace · 2d ago
- Patient death in BMS pulmonary fibrosis trial raises questions, but analysts unshakenThe revelation of a patient death in Bristol Myers Squibb’s phase 3 trial of a potential pulmonary fibrosis treatment has raised concerns ahead of the study’s readout, but analysts were quick to di…fiercebiotech · 2d ago
- Bristol Myers trial revisions shake confidence in new class of fibrosis drugsA spokesperson confirmed that a “limited number” of liver-related safety events, including a patient death, were observed in testing of Bristol Myers’ admilparant — though it’s unclear whether the…biopharma_dive · 3d ago
- J&J’s Contineum-partnered depression drug flunks another phase 2 testA phase 2 trial of Johnson & Johnson’s JNJ-5120 has missed its primary endpoint, denting the prospects of the Contineum Therapeutics-partnered depression drug candidate.fiercebiotech · 18d ago
- Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial failsBMS is barreling toward a clinical trial readout that an H.C. Wainwright analyst believes could contribute to the return of mergers between mega-cap drugmakers.biospace · 1mo ago
- As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca mergerWhile both drugmakers face looming patent cliffs, analysts say joining forces could help Bristol Myers Squibb replenish its eroding portfolio—while the strategic case for AstraZeneca seems to be mo…biospace · 2mo ago
- BMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this yearBMS may have been absent from the dealmaking spree of some of its Big Pharma peers this year, but that might not change anytime soon.fiercebiotech · 2mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that